Neutral · 50/100Oct 1, 12:46 PM EDT
Regeneron Slides as Early Ovarian Cancer Data Disappoints
REGNSNY
Regeneron Pharmaceuticals (REGN) reported initial Phase 1/2 trial results for ubamatamab, an experimental therapy for ovarian cancer, causing shares to drop after early gains tied to an expanded collaboration with Sanofi (SNY). The early-stage data likely rais…
- ▹Early-stage Phase 1/2 trial data for ubamatamab disappointed, causing a stock drop despite an expanded Sanofi collaboration.
- ▹Regeneron is a large-cap platform company with multiple assets, but this specific news is negative and early-stage, limiting near-term impact.
High Risk · 37/100Oct 1, 1:40 PM EDT
Nektar Shares Slide on Mixed Mid-Stage Results for Hair Loss Drug
NKTR
Nektar Therapeutics released additional data from the Phase 2 REZOLVE-AA trial of rezpegaldesleukin, a twice-monthly subcutaneous injection for hair loss. The stock dropped to near an eight-month low following the update. Investors are concerned about the drug…
- ▹Mid-stage trial data for hair loss drug disappoints, sending shares near 8-month low
- ▹Single-asset immunotherapy with no commercial product and unclear regulatory path
High Risk · 32/100Oct 1, 12:07 PM EDT
BTIG Downgrades Liquidia to Neutral Following Patent Loss to United Therapeutics
LQDAUTHR
BTIG downgraded Liquidia (LQDA) to Neutral from Buy after a court ruling favored rival United Therapeutics (UTHR), causing LQDA shares to plummet over 50% in the prior session. The patent decision is a major setback for Liquidia's competitive position, and the…
- ▹Patent loss to United Therapeutics triggers 50%+ sell-off and BTIG downgrade, severely damaging near-term commercial prospects.
- ▹Single-asset company with no platform diversification, high regulatory and legal risk, and uncertain path forward.